158 related articles for article (PubMed ID: 15352995)
1. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia.
Cacciola RR; Francesco ED; Giustolisi R; Cacciola E
Br J Haematol; 2004 Sep; 126(6):885-6. PubMed ID: 15352995
[No Abstract] [Full Text] [Related]
2. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.
Cacciola RR; Cipolla A; Di Francesco E; Giustolisi R; Cacciola E
Am J Hematol; 2005 Sep; 80(1):81-3. PubMed ID: 16138352
[TBL] [Abstract][Full Text] [Related]
3. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
[No Abstract] [Full Text] [Related]
4. Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.
Griesshammer M
Expert Rev Hematol; 2009 Jun; 2(3):227-36. PubMed ID: 21082965
[TBL] [Abstract][Full Text] [Related]
5. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide.
Andersson BS
Hematology; 2002 Jun; 7(3):173-7. PubMed ID: 12243981
[No Abstract] [Full Text] [Related]
6. Treatment of essential thrombocythemia with anagrelide.
Chintagumpala MM; Kennedy LL; Steuber CP
J Pediatr; 1995 Sep; 127(3):495-8. PubMed ID: 7658287
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of anagrelide in childhood essential thrombocythemia.
Kanai A; Morokawa H; Matsuda K; Shimazaki E; Nakazawa Y
Pediatr Int; 2017 Sep; 59(9):1017-1018. PubMed ID: 28707720
[No Abstract] [Full Text] [Related]
8. [Essential thrombocythemia: therapy with anagrelide].
Mazzucconi MG; Ferrari A; Balduini CL
Haematologica; 1991 Jun; 76 Suppl 3():378-81. PubMed ID: 1661268
[No Abstract] [Full Text] [Related]
9. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
[TBL] [Abstract][Full Text] [Related]
10. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
11. Long-term use of anagrelide in the treatment of children with essential thrombocythemia.
Lackner H; Urban C; Benesch M; Moser A; Sovinz P; Schwinger W; Dornbusch HJ
Eur J Haematol; 2006 Oct; 77(4):358-9. PubMed ID: 16856926
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
Ito T; Hashimoto Y; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S
Eur J Haematol; 2019 Aug; 103(2):116-123. PubMed ID: 31107982
[TBL] [Abstract][Full Text] [Related]
13. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
Cascavilla N; De Stefano V; Pane F; Pancrazzi A; Iurlo A; Gobbi M; Palandri F; Specchia G; Liberati AM; D'Adda M; Gaidano G; Fjerza R; Achenbach H; Smith J; Wilde P; Vannucchi AM
Drug Des Devel Ther; 2015; 9():2687-94. PubMed ID: 26028965
[TBL] [Abstract][Full Text] [Related]
14. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
15. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy.
Wong RS; Lam LW; Cheng G
Ann Hematol; 2008 Aug; 87(8):683-4. PubMed ID: 18299832
[No Abstract] [Full Text] [Related]
16. [Anagrelide for treatment of patients with essential thrombocythaemia].
Boban A; Sertić D; Radman I; Zupancić-Salek S; Zadro R; Labar B
Lijec Vjesn; 2008; 130(5-6):141-5. PubMed ID: 18792562
[TBL] [Abstract][Full Text] [Related]
17. [Hematologic Malignancies/Pediatric Malignancies. II. Treatment of Essential Thrombocythemia--The Role of Anagrelide].
Kitanaka A; Shimoda K
Gan To Kagaku Ryoho; 2016 May; 43(5):535-8. PubMed ID: 27344681
[No Abstract] [Full Text] [Related]
18. Treatment of essential thrombocythemia in childhood.
Scherer S; Ferrari R; Rister M
Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533
[TBL] [Abstract][Full Text] [Related]
19. [Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide].
Laguna MS; Kornblihtt LI; Marta RF; Molinas FC
Medicina (B Aires); 2000; 60(4):448-52. PubMed ID: 11188949
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
